Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2022, Cilt: 10 Sayı: 2, 165 - 170, 31.12.2022
https://doi.org/10.51354/mjen.1206365

Öz

Kaynakça

  • [1]. M. Clemons, S. Danson, and A. Howell, “Tamoxifen ('Nolvadex’): A review,” Cancer Treat. Rev., vol. 28, no. 4, pp. 165–180, 2002, doi: 10.1016/S0305-7372(02)00036-1.
  • [2]. D. J. Bentrem and V. Craig Jordan, “Tamoxifen, raloxifene and the prevention of breast cancer.,” Minerva Endocrinol., vol. 27, no. 2, pp. 127–139, 2002, doi: 10.1210/edrv.20.3.0368.
  • [3]. S. Mandlekar and A. N. T. Kong, “Mechanisms of tamoxifen-induced apoptosis,” Apoptosis, vol. 6, no. 6, pp. 469–477, 2001, doi: 10.1023/A:1012437607881.
  • [4]. M. Fouladgar, H. Karimi-Maleh, F. Opoku, and P. P. Govender, “Electrochemical anticancer drug sensor for determination of raloxifene in the presence of tamoxifen using graphene-CuO-polypyrrole nanocomposite structure modified pencil graphite electrode: Theoretical and experimental investigation,” J. Mol. Liq., vol. 311, p. 113314, 2020, doi: 10.1016/j.molliq.2020.113314.
  • [5]. I. Girault, I. Bièche, and R. Lidereau, “Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer,” Maturitas, vol. 54, no. 4, pp. 342–351, 2006, doi: 10.1016/j.maturitas.2006.06.003.
  • [6]. M. M. T. Buckley and K. L. Goa, “Tamoxifen: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use,” Drugs, vol. 37, no. 4, pp. 451–490, 1989, doi: 10.2165/00003495-198937040- 00004.
  • [7]. B. J. A. Furr and V. C. Jordan, “The pharmacology and clinical uses of tamoxifen,” Pharmacol. Ther., vol. 25, no. 2, pp. 127–205, 1984, doi: 10.1016/0163-7258(84)90043-3.
  • [8]. K. Lee, B. A. Ward, Z. Desta, D. A. Flockhart, and D. R. Jones, “Q uantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection : application to a clinical trial,” vol. 791, pp. 245–253, 2003.
  • [9]. X. Liu, J. Zhang, J. Yin, and H. Duan, “Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry,” pp. 2977–2985, 2010, doi: 10.1007/s00216-010-3531-0.
  • [10]. S. Xiao, Y. Yang, J. Zhang, Y. Wu, and B. Shao, “[Determination of 6 antiestrogens in fish tissues by ultra performance liquid chromatography-tandem mass spectrometry],” Se pu = Chinese J. Chromatogr., vol. 29, no. 11, p. 1055—1061, 2011, [Online]. Available: http://europepmc.org/abstract/MED/22393691.
  • [11]. K. Radhapyari, P. Kotoky, and R. Khan, “Detection of anticancer drug tamoxifen using biosensor based on polyaniline probe modified with horseradish peroxidase,” Mater. Sci. Eng. C, vol. 33, no. 2, pp. 583–587, 2013, doi: 10.1016/j.msec.2012.09.021.
  • [12]. S. Yanik, D. Ozkan-ariksoysal, and S. Yilmaz, “ELECTROCHEMICAL BIOSENSOR FOR BRCA1 GENE AND TAMOXIFEN INTERACTION,” vol. 4, no. 1, pp. 35–48, 2020.
  • [13]. L. Dornelles, S. Hernandez, G. Marrazza, M. Mascini, and L. Tatsuo, “Investigations of the antioxidant properties of plant extracts using a DNA-electrochemical biosensor,” vol. 21, pp. 1374–1382, 2006, doi: 10.1016/j.bios.2005.05.012.
  • [14]. E. Küpeli Akkol, I. Süntar, M. Ilhan, and E. Aras, “In vitro enzyme inhibitory effects of Rubus sanctus Schreber and its active metabolite as a function of wound healing activity,” J. Herb. Med., 2015, doi: 10.1016/j.hermed.2015.09.002.
  • [15]. I. Erlund et al., “Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers,” Eur. J. Clin. Pharmacol., vol. 56, no. 8, pp. 545–553, 2000, doi: 10.1007/s002280000197.
  • [16]. S. Allahverdiyeva, O. Yunusoğlu, Y. Yardım, and Z. Şentürk, “First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode,” Anal. Chim. Acta, vol. 1159, 2021, doi: 10.1016/j.aca.2021.338418.
  • [17]. H. Subak and D. Ozkan-Ariksoysal, “Label-free electrochemical biosensor for the detection of Influenza genes and the solution of guanine-based displaying problem of DNA hybridization,” Sensors Actuators, B Chem., vol. 263, 2018, doi: 10.1016/j.snb.2018.02.089

Electrochemical biosensor for simultaneously detection of Tamoxifen

Yıl 2022, Cilt: 10 Sayı: 2, 165 - 170, 31.12.2022
https://doi.org/10.51354/mjen.1206365

Öz

Cancer is described as the uncontrollably multiplying abnormal proliferation of cells. Cancer can affect everyone, and risk of which rises with age, lifestyle, and environmental toxins. Tamoxi̇fen (TAM) which is a selective estrogen receptor modulator, has estrogenic or antiestrogenic effects on the breast tissue by binding to the estrogen receptors. The current study presents a voltammetric biosensor to identify the effect of Tamoxifen on DNA structure. In this study, the effect of TAM on the double-stranded DNA (dsDNA) was investigated electrochemically in both the presence and absence of antioxidants. For this purpose, TAM-dsDNA-antioxidant interaction investigated by using the pencil graphite electrode (PGE). The DNA modified sensor was created simply by wet-adsorbtion method. The prepared biosensor was examined electrochemically by square wave voltammety (SWV) method, and its lowest concentration and optimum pH range were determined. The effect of TAM on dsDNA was investigated simultaneously for the first time in the literature.

Kaynakça

  • [1]. M. Clemons, S. Danson, and A. Howell, “Tamoxifen ('Nolvadex’): A review,” Cancer Treat. Rev., vol. 28, no. 4, pp. 165–180, 2002, doi: 10.1016/S0305-7372(02)00036-1.
  • [2]. D. J. Bentrem and V. Craig Jordan, “Tamoxifen, raloxifene and the prevention of breast cancer.,” Minerva Endocrinol., vol. 27, no. 2, pp. 127–139, 2002, doi: 10.1210/edrv.20.3.0368.
  • [3]. S. Mandlekar and A. N. T. Kong, “Mechanisms of tamoxifen-induced apoptosis,” Apoptosis, vol. 6, no. 6, pp. 469–477, 2001, doi: 10.1023/A:1012437607881.
  • [4]. M. Fouladgar, H. Karimi-Maleh, F. Opoku, and P. P. Govender, “Electrochemical anticancer drug sensor for determination of raloxifene in the presence of tamoxifen using graphene-CuO-polypyrrole nanocomposite structure modified pencil graphite electrode: Theoretical and experimental investigation,” J. Mol. Liq., vol. 311, p. 113314, 2020, doi: 10.1016/j.molliq.2020.113314.
  • [5]. I. Girault, I. Bièche, and R. Lidereau, “Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer,” Maturitas, vol. 54, no. 4, pp. 342–351, 2006, doi: 10.1016/j.maturitas.2006.06.003.
  • [6]. M. M. T. Buckley and K. L. Goa, “Tamoxifen: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use,” Drugs, vol. 37, no. 4, pp. 451–490, 1989, doi: 10.2165/00003495-198937040- 00004.
  • [7]. B. J. A. Furr and V. C. Jordan, “The pharmacology and clinical uses of tamoxifen,” Pharmacol. Ther., vol. 25, no. 2, pp. 127–205, 1984, doi: 10.1016/0163-7258(84)90043-3.
  • [8]. K. Lee, B. A. Ward, Z. Desta, D. A. Flockhart, and D. R. Jones, “Q uantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection : application to a clinical trial,” vol. 791, pp. 245–253, 2003.
  • [9]. X. Liu, J. Zhang, J. Yin, and H. Duan, “Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry,” pp. 2977–2985, 2010, doi: 10.1007/s00216-010-3531-0.
  • [10]. S. Xiao, Y. Yang, J. Zhang, Y. Wu, and B. Shao, “[Determination of 6 antiestrogens in fish tissues by ultra performance liquid chromatography-tandem mass spectrometry],” Se pu = Chinese J. Chromatogr., vol. 29, no. 11, p. 1055—1061, 2011, [Online]. Available: http://europepmc.org/abstract/MED/22393691.
  • [11]. K. Radhapyari, P. Kotoky, and R. Khan, “Detection of anticancer drug tamoxifen using biosensor based on polyaniline probe modified with horseradish peroxidase,” Mater. Sci. Eng. C, vol. 33, no. 2, pp. 583–587, 2013, doi: 10.1016/j.msec.2012.09.021.
  • [12]. S. Yanik, D. Ozkan-ariksoysal, and S. Yilmaz, “ELECTROCHEMICAL BIOSENSOR FOR BRCA1 GENE AND TAMOXIFEN INTERACTION,” vol. 4, no. 1, pp. 35–48, 2020.
  • [13]. L. Dornelles, S. Hernandez, G. Marrazza, M. Mascini, and L. Tatsuo, “Investigations of the antioxidant properties of plant extracts using a DNA-electrochemical biosensor,” vol. 21, pp. 1374–1382, 2006, doi: 10.1016/j.bios.2005.05.012.
  • [14]. E. Küpeli Akkol, I. Süntar, M. Ilhan, and E. Aras, “In vitro enzyme inhibitory effects of Rubus sanctus Schreber and its active metabolite as a function of wound healing activity,” J. Herb. Med., 2015, doi: 10.1016/j.hermed.2015.09.002.
  • [15]. I. Erlund et al., “Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers,” Eur. J. Clin. Pharmacol., vol. 56, no. 8, pp. 545–553, 2000, doi: 10.1007/s002280000197.
  • [16]. S. Allahverdiyeva, O. Yunusoğlu, Y. Yardım, and Z. Şentürk, “First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode,” Anal. Chim. Acta, vol. 1159, 2021, doi: 10.1016/j.aca.2021.338418.
  • [17]. H. Subak and D. Ozkan-Ariksoysal, “Label-free electrochemical biosensor for the detection of Influenza genes and the solution of guanine-based displaying problem of DNA hybridization,” Sensors Actuators, B Chem., vol. 263, 2018, doi: 10.1016/j.snb.2018.02.089
Toplam 17 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Mühendislik
Bölüm Araştırma Makalesi
Yazarlar

Hasret Subak 0000-0003-0100-2529

Erken Görünüm Tarihi 31 Aralık 2022
Yayımlanma Tarihi 31 Aralık 2022
Yayımlandığı Sayı Yıl 2022 Cilt: 10 Sayı: 2

Kaynak Göster

APA Subak, H. (2022). Electrochemical biosensor for simultaneously detection of Tamoxifen. MANAS Journal of Engineering, 10(2), 165-170. https://doi.org/10.51354/mjen.1206365
AMA Subak H. Electrochemical biosensor for simultaneously detection of Tamoxifen. MJEN. Aralık 2022;10(2):165-170. doi:10.51354/mjen.1206365
Chicago Subak, Hasret. “Electrochemical Biosensor for Simultaneously Detection of Tamoxifen”. MANAS Journal of Engineering 10, sy. 2 (Aralık 2022): 165-70. https://doi.org/10.51354/mjen.1206365.
EndNote Subak H (01 Aralık 2022) Electrochemical biosensor for simultaneously detection of Tamoxifen. MANAS Journal of Engineering 10 2 165–170.
IEEE H. Subak, “Electrochemical biosensor for simultaneously detection of Tamoxifen”, MJEN, c. 10, sy. 2, ss. 165–170, 2022, doi: 10.51354/mjen.1206365.
ISNAD Subak, Hasret. “Electrochemical Biosensor for Simultaneously Detection of Tamoxifen”. MANAS Journal of Engineering 10/2 (Aralık 2022), 165-170. https://doi.org/10.51354/mjen.1206365.
JAMA Subak H. Electrochemical biosensor for simultaneously detection of Tamoxifen. MJEN. 2022;10:165–170.
MLA Subak, Hasret. “Electrochemical Biosensor for Simultaneously Detection of Tamoxifen”. MANAS Journal of Engineering, c. 10, sy. 2, 2022, ss. 165-70, doi:10.51354/mjen.1206365.
Vancouver Subak H. Electrochemical biosensor for simultaneously detection of Tamoxifen. MJEN. 2022;10(2):165-70.

Manas Journal of Engineering 

16155